Pfizer Inc. announced on Monday that it is halting the development of its daily pill for chronic weight management, danuglipron, after one of the participants in the trial experienced drug-induced liver injury.
The company stated that a participant in one of the dose-optimization studies experienced a liver enzyme elevation but did not have any liver-related symptoms or side effects. The enzymes returned to their normal levels once the patient stopped taking the pill.
"Cardiovascular and metabolic diseases including obesity remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR [gastric inhibitory polypeptide receptor] antagonist candidate and other earlier obesity programs," Pfizer's Chief Scientific Officer and President of R&D Chris Boshoff said.
